The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

Sutter Health, OSF HealthCare, University Hospitals and others are entering expensive, long-term partnerships for key devices ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

To address these shortages, the FDA has put measures into place, including expedited review processes and the use of enforcement discretion. The FDA also now requires manufacturers to give at least ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Key Takeaways Johnson & Johnson's fourth quarter sales met estimates, while net income fell short.After adjusting for ...

Johnson & Johnson, fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular, reported fourth-quarter sales ...

Meridian Medical Technologies, a unit of CDMO Kindeva, snared a $129 million contract to supply the United States with the ...

Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...